312611-92-0

Basic information

• Product Name: VK-28
• Synonyms: 5-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]quinolin-8-ol
• CAS NO: 312611-92-0
• Molecular Formula: C16H21N3O2
• Molecular Weight: 287.361
• Mol File: 312611-92-0.mol

Chemical Properties

• Melting Point: >230℃
• Appearance: off-white/solid
• Storage Temp.: 2-8°C
• Solubility: H2O: insoluble
• CAS DataBase Reference: VK-28(CAS DataBase Reference)
• NIST Chemistry Reference: VK-28(312611-92-0)
• EPA Substance Registry System: VK-28(312611-92-0)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• WGK Germany: 3
• Hazardous Substances Data: 312611-92-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
VK-28 is used as a neuroprotective agent for its potential to mitigate the effects of oxidative stress and inflammation, which are key contributors to neurodegenerative diseases. Its antioxidant and anti-inflammatory properties make it a valuable asset in the development of treatments for conditions like Parkinson's and Alzheimer's.
Used in Neurodegenerative Disease Research:
VK-28 is utilized as a research tool to investigate the underlying mechanisms of neuroprotection, particularly in the context of its ability to regulate dopamine levels in the brain. This research is crucial for advancing our understanding of the compound's therapeutic applications and its potential role in the treatment of neurodegenerative disorders.

Upstream product

• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 4053-45-6 5-chloromethyl-8-hydroxyquinoline hydrochloride 
• 148-24-3 8-quinolinol 

Relevant articles and documents

Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators

Use of a compound of formula (I), wherein R1 is H or hydrocarbyl; R2 is a hydrophobic radical; R3 is 3-(C2-C6)acyl-4-hydroxyphenyl, 3-hydroxyimino (C2-C6)-alkyl-4-hydroxyphenyl, or COOZ, wherein Z is H, (C1-C6) alkyl, aryl, aryl or ar(C1-C6) alkyl; and n is 1-20; and of a compound of formula (II), wherein R4 is (C1-C6) alkyl, cyano (C1-C6) alkyl, (C1-C6) alkoxy (C1-C6) alkyl or —CH2NR7R8, wherein R7 and R8, the same or different, is each H or (C1-C6) alkyl, or together with the N atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from N, O or S, the further N atom being optionally substituted, and either R5 is H and R6 is (C2-C6) acyl or hydroxyimino (C2-C6) alkyl, or R5 and R6 together with the phenyl ring form a quinoline, a 1,2,3,4-tetrahydroquinoline or a perhydroquinoline ring, for the preparation of pharmaceutical compositions for the treatment of Parkinson's disease or stroke.

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases

Several novel antioxidant-iron chelators bearing 8-hydroxyoxyquinoline moiety were synthesized, and various properties related to their iron chelation, and neuroprotective action were investigated. All the chelators exhibited strong iron(III) chelating and high antioxidant properties. Chelator 9 (HLA20), having good permeability into K562 cells and moderate selective MAO-B inhibitory activity (IC50 110 μM), displayed the hightest protective effects against differentiated P19 cell death induced by 6-hydroxydopamine. EPR studies suggested that Chelator 9 also act as radical scavenger to directly scavenge hydroxyl radical.